Claims
- 1. A compound of the formula:
- 2. The compound of claim 1 wherein at least one of the R and R1 substituent group is substituted with one or more moieties selected from the group consisting of C1-C10 alkyl, C1-C10 alkoxy, and aryl, and wherein the moiety is substituted or unsubstituted.
- 3. The compound of claim 2 wherein the moiety is substituted with one or more groups selected from the group consisting of halogen, a C1-C5 alkyl, C1-C5 alkoxy, and phenyl.
- 4. The compound of claim 1 wherein R is hydrogen and R1 is selected from the group consisting Of C1-C20 alkyl, C2-C20 alkenyl, and aryl.
- 5. The compound of claim 4 wherein R1 is phenyl or vinyl.
- 6. The compound of claim 1 wherein X and X1 are each independently hydrogen, halide, or selected from the group consisting of C1-C20 alkyl, aryl, C1-C20 alkoxide, aryloxide, C3-C20 alkyldiketonate, aryldiketonate, C1-C20 carboxylate, arylsulfonate, C1-C20 alkylsulfonate, C1-C20 alkylthio, C1-C20 alkylsulfonyl, or C1-C20 alkylsulfinyl, wherein X and X1 is each independently substituted or unsubstituted.
- 7. The compound of claim 6 wherein at least one of X and X1 is substituted with one or more moieties selected from the group consisting of C1-C10 alkyl, C1-C10 alkoxy, and aryl, wherein the moiety is substituted or unsubstituted.
- 8. The compound of claim 7 wherein the moiety is substituted with one or more groups selected from the group consisting of halogen, C1-C5 alkyl, C1-C5 alkoxy, and phenyl.
- 9. The compound of claim 1 wherein X and X1 are each independently selected from the group consisting of halide, benzoate, C1-C5 carboxylate, C1-C5 alkyl, phenoxy, C1-C5 alkoxy, C1-C5 alkylthio, aryl, and C1-C5 alkyl sulfonate.
- 10. The compound of claim 9 wherein X and X1 are each independently selected from the group consisting of halide, CF3CO2, CH3CO2, CFH2CO2, (CH3)3CO, (CF3)2(CH3)CO, (CF3)(CH3)2CO, PhO, MeO, EtO, tosylate, mesylate, or trifluoromethanesulfonate.
- 11. The compound of claim 1 wherein L, L1′ and L2 are each independently selected from the group consisting of a monodentate, bidentate or tetradentate neutral electron donor ligand.
- 12. The compound of claim 11 wherein L, L1′ and L are each independently selected from the group consisting of phosphine, sulfonated phosphine, phosphite, phosphinite, phosphonite, arsine, stibine, ether, amine, amide, imine, sulfoxide, carboxyl, nitrosyl, pyridine, and thioether, N-heterocyclic carbene ligand or any derivatives therefrom.
- 13. The compound of claim 1 wherein both L1′ and L2 are either the same or different N-heterocyclic carbene ligands.
- 14. The compound of claim 1 wherein the N-heterocyclic carbene ligand is selected from the group consisting of:
- 15. The compound of claim 1 wherein L is an N-heterocyclic carbene ligand, and L1′ and L2 are each heterocyclic ligands.
- 16. The compound of claim 15 wherein at least one of L1 and L2 is aromatic
- 17. The compound of claim 15 wherein L1′ and L2 together form a bidenatate ligand.
- 18. The compound of claim 1 at least one of L1′ and L2 is a unsubstituted or substituted heteroarene selected from the group consisting of furan, thiophene, pyrrole, pyridine, bipyridine, picolylimine, gamma-pyran, gamma-thiopyran, phenanthroline, pyrimidine, bipyrimidine, pyrazine, indole, coumarone, thionaphthene, carbazole, dibenzofuran, dibenzothiophene, pyrazole, imidazole, benzimidazole, oxazole, thiazole, dithiazole, isoxazole, isothiazole, quinoline, bisquinoline, isoquinoline, bisisoquinoline, acridine, chromene, phenazine, phenoxazine, phenothiazine, triazine, thianthrene, purine, bisimidazole and bisoxazole.
- 19. The compound of claim 18 wherein at least one of L1′ and L2 is a substituted or unsubstituted pyridine or a substituted or unsubstituted pyridine derivative.
- 20. The compound of claim 18 wherein the substituted or unsubstituted heteroarene is selected from the group consisting of:
- 21. The compound of claim 1 wherein at least one of L1′ and L2 is a unsubstituted or substituted heterocycle selected from the group consisting of:
- 22. A compound of the formula:
- 23. The compound of claim 22 wherein X and X1 are each Cl, L is (IMesH2), L1′ and L2 are each independently a pyridine or pyridine derivative; R is hydrogen and R is phenyl or vinyl.
- 24. A compound selected from the group consisting of:
- 25. A method for the metathesis of a cyclic or acyclic olefin comprising contacting the olefin with a compound of the formula:
- 26. The method of claim 25 wherein M is ruthenium;
X and X1 are each independently selected from the group consisting of halide, CF3CO2, CH3CO2, CFH2CO2, (CH3)3CO, (CF3)2(CH3)CO, (CF3)(CH3)2CO, PhO, MeO, EtO, tosylate, mesylate, or trifluoromethanesulfonate; L is an N-heterocyclic carbene ligand; L1′ and L2 are the same or different and are each a substituted or unsubstituted heteroarene; R is hydrogen and R1 is selected from the group consisting of C1-C20 alkyl, C2-C20 alkenyl, and aryl.
- 27. The method of claim 26 wherein X and X1 are each Cl, L is (IMesH2), L1′ and L2 are each independently a pyridine or pyridine derivative; R is hydrogen and R1 is phenyl or vinyl.
- 28. A method for the ring-opening metathesis polymerization of a cyclic olefin comprising contacting the olefin with a compound of the formula
- 29. The method of claim 28 wherein the olefin is substituted or unsubstituted norbornene or a norbornene derivative.
- 30. The method of claim 29 wherein the olefin is substituted or unsubstituted dicyclopentadiene.
- 31. A compound of the formula:
- 32. The compound of claim 31 wherein R1 is substituted or unsubstituted vinyl.
- 33. A method for the synthesis of a ruthenium or osmium hexacoordinated metathesis catalyst comprising contacting a ruthenium or osmium pentacoordinated metal carbene metathesis catalyst comprising at least one N-heterocyclic carbene ligand with a neutral electron donor ligand.
- 34. The method of claim 33 wherein the catalyst is of the formula:
- 35. The method of claim 33 wherein R is hydrogen and R1 is selected from the group consisting of C1-C20 alkyl, C2-C20 alkenyl, and aryl.
- 36. The method of claim 34 wherein R1 is phenyl or vinyl.
- 37. The method of claim 33 wherein X and X1 are each independently selected from the group consisting of halide, benzoate, C1-C5 carboxylate, C1-C5 alkyl, phenoxy, C1-C5 alkoxy, C1-C5 alkylthio, aryl, and C1-C5 alkyl sulfonate.
- 38. The method of claim 37 wherein X and X1 are each independently selected from the group consisting of halide, CF3CO2, CH3CO2, CFH2CO2, (CH3)3CO, (CF3)2(CH3)CO, (CF3)(CH3)2CO, PhO, MeO, EtO, tosylate, mesylate, or trifluoromethanesulfonate.
- 39. The method of claim 33 wherein L, L1′ and L2 are each independently selected from the group consisting of a monodentate, bidentate or tetradentate neutral electron donor ligand.
- 40. The method of claim 33 wherein L, L1′ and L2 are each independently selected from the group consisting of phosphine, sulfonated phosphine, phosphite, phosphinite, phosphonite, arsine, stibine, ether, amine, amide, imine, sulfoxide, carboxyl, nitrosyl, pyridine, and thioether, N-heterocyclic carbene ligand or any derivatives therefrom.
- 41. The method of claim 40 wherein both L1′ and L2 are either the same or different N-heterocyclic carbene ligands.
- 42. The method of claim 40 wherein the N-heterocyclic carbene ligand is selected from the group consisting of:
- 43. The method of claim 33 wherein L is an N-heterocyclic carbene ligand, and L1′ and L2 are each heterocyclic ligands.
- 44. The method of claim 33 at least one of L′ and L2 is a unsubstituted or substituted heteroarene selected from the group consisting of furan, thiophene, pyrrole, pyridine, bipyridine, picolylimine, gamma-pyran, gamma-thiopyran, phenanthroline, pyrimidine, bipyrimidine, pyrazine, indole, coumarone, thionaphthene, carbazole, dibenzofuran, dibenzothiophene, pyrazole, imidazole, benzimidazole, oxazole, thiazole, dithiazole, isoxazole, isothiazole, quinoline, bisquinoline, isoquinoline, bisisoquinoline, acridine, chromene, phenazine, phenoxazine, phenothiazine, triazine, thianthrene, purine, bisimidazole and bisoxazole.
- 45. The method of claim 44 wherein at least one of L1′ and L2 is a substituted or unsubstituted pyridine or a substituted or unsubstituted pyridine derivative.
- 46. The method of claim 33 wherein at least one of L1′ and L2 is a unsubstituted or substituted heterocycle selected from the group consisting of:
- 47. A method for the synthesis of a ruthenium or osmium hexacoordinated metathesis catalyst of the formula:
- 48. A method for polymerizing an olefin comprising:
contacting a compound of the formula: 47with a compound of the formula: 48and a cyclic or acyclic olefin; wherein M is ruthenium or osmium; X and X1 are the same or different and are each independently any anionic ligand; L, L1′, and L2 are the same or different and are each independently any neutral electron donor ligand; wherein at least one of L, L1′, and L2 is an N-heterocyclic carbene ligand; R , R1, R6, R7, R8, R9, R10 and R11 are the same or different and are each independently hydrogen or a substituted or unsubstituted substituent selected from the group consisting of C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, aryl, C1-C20 carboxylate, C1-C20 alkoxy, C2-C20 alkenyloxy, C2-C20 alkynyloxy, aryloxy, C2-C20 alkoxycarbonyl, C1-C20 alkylthio, C1-C20 alkylsulfonyl and C1-C20 alkylsulfinyl; and A is hydrogen and B is selected from the group consisting of CCl3; CH2SO2Ph; C6F5; OR21; and N(R22)(R23), wherein R21 is selected from the group consisting of Me, C2H5, i-C3H7, CH2CMe3, CMe3, C6H11 (cyclohexyl), CH2Ph, CH2norbornyl, CH2norbomenyl, C6H5, 2,4,6-(CH3)3C6H2 (mesityl), 2,6-1-Pr2C6H2, 4-Me-C6H4 (tolyl), 4-C1-C6H4; and wherein R22 and R23 are each independently selected from the group consisting of Me, C2H5, i-C3H7, CH2CMe3, CMe3, C6H11 (cyclohexyl), CH2Ph, CH2norbomyl, CH2norbomenyl, C6H5, 2,4,6-(CH3)3C6H2 (mesityl), 2,6-i-Pr2C6H2, 4-Me-C6H4 (tolyl), 4-C1-C6H4).
- 49. The method of claim 48 wherein
M is ruthenium; X and X1 are each independently selected from the group consisting of halide, CF3CO2, CH3CO2, CFH2CO2, (CH3)3CO, (CF3)2(CH3)CO, (CF3)(CH3)2CO, PhO, MeO, EtO, tosylate, mesylate, or trifluoromethanesulfonate; L is an N-heterocyclic carbene ligand; L1′ and L2 are the same or different and are each a substituted or unsubstituted heteroarene; R is hydrogen and R1, R6, R7, R8, R9, R10, R11 are each independently selected from the group consisting of hydrogen, C1-C20 alkyl, C2-C20 alkenyl, and aryl; A is hydrogen and B is CCl3.
Parent Case Info
[0001] This application claims the benefit of U.S. Provisional Patent Application No. 60/314,978 filed Aug. 24, 2001 [Attorney Docket No. CIT-3525-P]; U.S. Provisional Application No. 60/278,311 filed Mar. 23, 2001 [Attorney Docket No. 014516-0278350 (CYM-100)]; U.S. Provisional Application No. 60/288,680 filed May 3, 2001 [Attorney Docket No. 014516-0278290 (CYM-110)]; U.S. Provisional Application No. 60/309,806 filed Aug. 1, 2001 [Attorney Docket No. CIT-3517] and U.S. Provisional Application No. 60/281,046 filed Apr. 2, 2001 [Attorney Docket No. CIT-3430], and U.S. patent application Ser. No. 09/948,115, filed Sep. 5, 2001 [Attorney Docket No. CIT-3282], the contents of each of which are incorporated herein by reference.
Government Interests
[0002] The U.S. Government has certain rights in this invention pursuant to Grant No. CHE-9809856 awarded by the National Science Foundation.
Provisional Applications (5)
|
Number |
Date |
Country |
|
60314978 |
Aug 2001 |
US |
|
60278311 |
Mar 2001 |
US |
|
60288680 |
May 2001 |
US |
|
60309806 |
Aug 2001 |
US |
|
60281046 |
Apr 2001 |
US |